Evidence map›Paper›PMID 30969970›Full record

ArticlePloS one2019

Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens.

Kathryn A Mesa, Bin Yu, Terri Wrin, Christos J Petropoulos, Grant H Pogson, David L Alexander, Gerardo Perez, Sara M O'Rourke, Faruk Sinangil, Joseph Robinson and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kathryn A MesaDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, CA, United States of America.ORCID 0000-0002-6521-534X
Bin YuDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, CA, United States of America.
Terri WrinMonogram Biosciences, South San Francisco, CA, United States of America.
Christos J PetropoulosMonogram Biosciences, South San Francisco, CA, United States of America.
Grant H PogsonDepartment of Ecology and Evolutionary Biology, University of California Santa Cruz, Santa Cruz, CA, United States of America.
David L AlexanderDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, CA, United States of America.
Gerardo PerezDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, CA, United States of America.
Sara M O'RourkeDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, CA, United States of America.
Faruk SinangilGlobal Solutions for Infectious Diseases, South San Francisco, California, United States of America.
Joseph RobinsonThe Conant Medical Foundation, San Francisco, California, United States of America.
Marcus A ConantThe Conant Medical Foundation, San Francisco, California, United States of America.
Phillip W BermanDepartment of Biomolecular Engineering, Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, CA, United States of America.
University of California, Santa Cruz · USGlobal Solutions for Infectious Diseases · US

Funding

Enhanced Anti-HIV-1 Antibody Responses in African American Women Seropositive forR01DA036335 · NIDA · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BERMAN, PHILLIP WAYNE · 2013 to 2017
$3.0M
NIDA NIH HHS R01 DA036335
6 · The paper itself

Abstract

A major challenge in HIV vaccine development is the identification of immunogens able to elicit broadly neutralizing antibodies (bNAbs). While remarkable progress has been made in the isolation and characterization of bNAbs, the epitopes they recognize appear to be poorly immunogenic. Thus, none of the candidate vaccines developed to date has induced satisfactory levels of neutralizing antibodies to the HIV envelope protein (Env). One approach to the problem of poor immunogenicity is to build vaccines based on envelope (env) genes retrieved from rare individuals termed elite neutralizers (ENs) who at one time possessed specific sequences that stimulated the formation of bNAbs. Env proteins selected from these individuals could possess uncommon, yet to be defined, structural features that enhance the immunogenicity of epitopes recognized by bNAbs. Here we describe the recovery of envs from an EN that developed unusually broad and potent bNAbs. As longitudinal specimens were not available, we combined plasma and provirus sequences acquired from a single time-point to infer a phylogenetic tree. Combining ancestral reconstruction data with virus neutralization data allowed us to sift through the myriad of virus quasi-species that evolved in this individual to identify envelope sequences from the nodes that appeared to define the transition from neutralization sensitive envs to the neutralization resistant envs that occur in EN plasma. Synthetic genes from these nodes were functional in infectivity assays and sensitive to neutralization by bNAbs, and may provide a novel source of immunogens for HIV vaccine development.

Indexed as

AIDS VaccinesBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesHIVHIV AntibodiesHIV AntigensHIV InfectionsHumansImmunogenicity, VaccineNeutralization TestsPhylogenyProvirusesAIDS VaccinesBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesHIV Antigens

Identifiers

PMID30969970
PMCPMC6457492
OpenAlexW2937281245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.